Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 8.33%-19.46M | 32.56%-3.65M | 63.06%-1.93M | -26.59%-8.18M | -38.09%-5.7M | 10.62%-21.23M | -31.85%-5.41M | 14.25%-5.23M | -8.26%-6.46M | 45.55%-4.13M |
Net income from continuing operations | -28.40%-26.9M | -38.37%-6.49M | -77.25%-7.43M | -0.90%-6.83M | -16.00%-6.15M | 39.68%-20.95M | 33.63%-4.69M | 64.64%-4.19M | 19.81%-6.76M | 28.07%-5.3M |
Depreciation and amortization | 0.59%2.23M | 2.34%568K | -1.60%552K | 1.46%557K | 0.18%557K | 32.72%2.22M | 0.02%555K | 4.55%561K | 37.56%549K | 204.16%556K |
Other non cash items | 86.04%4.41M | 102.57%3.94M | 153.54%159K | -69.53%156K | -26.67%154K | -36.22%2.37M | -43.50%1.95M | -321.97%-297K | 4,671.43%512K | 39.63%210K |
Change In working capital | 103.95%198K | 43.27%-1.86M | 437.84%4.47M | -164.44%-2.1M | -182.86%-319K | -214.63%-5.01M | -100.93%-3.28M | -127.98%-1.32M | -141.87%-793K | 161.66%385K |
-Change in prepaid assets | -55.87%-279K | -177.78%-259K | 33.56%601K | 108.29%45K | -58.95%-666K | -127.02%-179K | -50.19%333K | 346.04%450K | -736.58%-543K | -557.92%-419K |
-Change in payables and accrued expense | 126.09%1.11M | 58.41%-1.44M | 347.91%4.03M | -1,791.43%-1.99M | -47.15%501K | -204.16%-4.24M | -58.67%-3.46M | -132.22%-1.63M | -105.84%-105K | 260.95%948K |
-Change in other current liabilities | -7.33%-630K | -7.33%-161K | -7.43%-159K | -7.59%-156K | -6.94%-154K | -53.58%-587K | -26.26%-150K | -12.38%-148K | -957.99%-145K | 3.10%-144K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 8.33%-19.46M | 32.56%-3.65M | 63.06%-1.93M | -26.61%-8.18M | -38.06%-5.7M | 10.62%-21.23M | -31.85%-5.41M | 14.25%-5.23M | -8.24%-6.46M | 45.53%-4.13M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -76.81%-366K | 74.31%-28K | -123.47%-219K | -98K | -21K | 95.75%-207K | -158.29%-109K | -174.02%-98K | 0 | 0 |
Net PPE purchase and sale | -76.81%-366K | 74.31%-28K | -123.47%-219K | ---98K | ---21K | -1,480.00%-207K | -102.25%-109K | -174.02%-98K | --0 | --0 |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -76.81%-366K | 74.31%-28K | -123.47%-219K | ---98K | ---21K | 95.75%-207K | -158.29%-109K | -174.02%-98K | --0 | --0 |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -23.24%18.42M | -44.38%2.42M | -85.33%1.03M | 23.48%8.78M | 11.83%6.19M | 514.73%23.99M | -0.35%4.34M | 6,193.12%7M | 4,263.35%7.11M | 3,380.21%5.54M |
Net issuance payments of debt | -21.45%18.42M | -44.39%2.42M | -85.39%1.03M | 40.86%8.78M | 6.08%6.19M | 471.40%23.44M | -4.70%4.34M | 6,217.49%7.03M | 3,749.88%6.23M | 3,557.94%5.84M |
Net common stock issuance | --0 | --0 | --0 | ---- | ---- | --659K | --0 | --0 | ---- | ---- |
Net other financing activities | ---- | ---- | ---- | ---- | ---- | 44.50%-111K | ---1K | ---28K | --218K | ---300K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -23.24%18.42M | -44.38%2.42M | -85.33%1.03M | 23.48%8.78M | 11.83%6.19M | 514.73%23.99M | -0.35%4.34M | 6,193.12%7M | 4,263.35%7.11M | 3,380.21%5.54M |
Net cash flow | ||||||||||
Beginning cash position | 396.74%3.2M | -30.23%3.06M | 54.55%4.18M | 78.97%3.68M | 396.74%3.2M | -97.46%645K | 912.25%4.38M | -58.47%2.7M | -86.42%2.05M | -97.46%645K |
Current changes in cash | -155.06%-1.41M | -7.23%-1.26M | -167.00%-1.12M | -22.62%503K | -66.50%472K | 110.36%2.56M | -653.41%-1.18M | 127.58%1.68M | 107.55%650K | 113.77%1.41M |
End cash Position | -43.98%1.8M | -43.98%1.8M | -30.23%3.06M | 54.55%4.18M | 78.97%3.68M | 396.59%3.2M | 396.59%3.2M | 912.25%4.38M | -58.47%2.7M | -86.42%2.05M |
Free cash flow | 7.50%-19.82M | 33.38%-3.68M | 59.62%-2.15M | -28.12%-8.28M | -38.57%-5.72M | 25.13%-21.43M | -32.65%-5.52M | 10.70%-5.33M | 23.46%-6.46M | 58.97%-4.13M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |